2010年3月8日,，美國科學(xué)家們對接受基因檢測的患者進(jìn)行跟蹤調(diào)查,，結(jié)果發(fā)現(xiàn)，有1/3的乳腺癌早期患者在接受基因組檢測后,，沒有感覺到這些檢測結(jié)果對治療行為具有指導(dǎo)意義,，因不能理解基因組檢測的數(shù)據(jù)意義無法與主治醫(yī)生討論相關(guān)治療問題，她們普遍關(guān)注的問題是,，通過基因檢測后是否能預(yù)測復(fù)發(fā)的記錄,。有1/4的患者表示，接受基因檢測結(jié)果后,，感到沮喪,。這篇關(guān)于癌癥早期基因組檢測的爭議性文章發(fā)表在Cancer在線版上。
來自Lineberger Comprehensive Cancer Center的科學(xué)家對乳腺癌患者基因檢測提出質(zhì)疑,?；蚪M檢測在早期乳腺癌患者中變得越來越常見，基因檢測過程主要探測21個與乳腺癌相關(guān)的基因,，在接受外科手術(shù)后,，這些基因的表達(dá)量可以預(yù)示乳腺癌的復(fù)發(fā)幾率。這些檢測結(jié)果可以幫助患者與醫(yī)生,，指導(dǎo)治療策略,，比如，是否通過化療來解決復(fù)發(fā)問題,。
如果被檢測者顯示出具有較高的復(fù)發(fā)率,，那么醫(yī)生將給患者更為激烈的治療方案,；如果被檢測者顯示出較低的復(fù)發(fā)率，那么醫(yī)生將采取相對保守的治療方案,。
在為期5年的跟蹤調(diào)查中,，科學(xué)家們對接受乳腺癌風(fēng)險基因檢測的患者進(jìn)行問卷調(diào)查，結(jié)果發(fā)現(xiàn),，大部分的患者表示愿意接受這種檢測,，并且相信這個檢測對乳腺癌的治療和預(yù)防復(fù)發(fā)具有積極的意義，但是,，仍舊有部分（1/3）患者表示,，雖然進(jìn)行了檢查，但是卻不能了解檢測結(jié)果的真正含義,，有1/4的患者表示,，對檢測結(jié)果表示出更大的焦慮。
這些結(jié)果表明,，基因檢測變得越來越常規(guī),，患者也十分接受這種檢測，但是,，美中不足的是,，醫(yī)生與患者間的溝通解釋比較缺乏，還有更一步上升的空間,。(生物谷Bioon.com)
生物谷推薦原文出處：
Cancer doi:10.1002/cncr.24990
Women's experiences with genomic testing for breast cancer recurrence risk
Janice P. Tzeng, MPH 1, Deborah Mayer, PhD, RN 2, Alice R. Richman, PhD 1, Isaac Lipkus, PhD 3, Paul K. Han, MD, MA, MPH 4, Carmina G. Valle, MPH 5, Lisa A. Carey, MD 6, Noel T. Brewer, PhD 1 *
1Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, North Carolina
2School of Nursing, University of North Carolina, Chapel Hill, North Carolina
3School of Nursing, Duke University, Durham, North Carolina
4Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
5Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina
6Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
ABSTRACT
BACKGROUND:
Few studies have examined how patients understand and use genomic test results when deciding about treatment. This study examined how women receive and incorporate results of Oncotype DX, a genomic test that offers recurrence risk estimates, into decisions about adjuvant treatment for early stage breast cancer.
METHODS:
Participants in the cross-sectional study were 77 women with early stage, estrogen receptor-positive breast cancer with 0 to 3 positive lymph nodes who received Oncotype DX between 2004 and 2009. Mailed surveys, supplemented by medical chart review, assessed how women received and understood recurrence risk information based on the test.
